Abstract：
BACKGROUND: Men exhibit higher prevalence of modifiable risk factors, such as smoking and alcohol consumption, leading to greater cancer incidence and lower survival rates. Comprehensive evidence on global cancer burden among men, including disparities by age group and country, is sparse. To address this, the authors analyzed 30 cancer types among men in 2022, with projections estimated for 2050.
METHODS: The 2022 GLOBOCAN estimates were used to describe cancer statistics for men in 185 countries/territories worldwide. Mortality-to-incidence ratios (MIRs) were calculated by dividing age-standardized mortality rates by incidence rates.
RESULTS: In 2022, a high MIR (indicating poor survival) was observed among older men (aged 65 years and older; 61%) for rare cancer types (pancreatic cancer, 91%) and in countries with low a Human Development Index (HDI; 74%). Between 2022 and 2050, cancer cases are projected to increase from 10.3 million to 19 million (≥84%). Deaths are projected to increase from 5.4 million to 10.5 million (≥93%), with a greater than two-fold increase among men aged 65 years and older (≥117%) and for low-HDI and medium-HDI countries/territories (≥160%). Cancer cases and deaths are projected to increase among working-age groups (≥39%) and very-high-HDI countries/territories (≥50%).
CONCLUSIONS: Substantial disparities in cancer cases and deaths were observed among men in 2022, and these are projected to widen by 2050. Strengthening health infrastructure, enhancing workforce quality and access, fostering national and international collaborations, and promoting universal health coverage are crucial to reducing cancer disparities and ensuring cancer equity among men globally.
METHODS: The 2022 GLOBOCAN estimates were used to describe cancer statistics for men in 185 countries/territories worldwide. Mortality-to-incidence ratios (MIRs) were calculated by dividing age-standardized mortality rates by incidence rates.
RESULTS: In 2022, a high MIR (indicating poor survival) was observed among older men (aged 65 years and older; 61%) for rare cancer types (pancreatic cancer, 91%) and in countries with low a Human Development Index (HDI; 74%). Between 2022 and 2050, cancer cases are projected to increase from 10.3 million to 19 million (≥84%). Deaths are projected to increase from 5.4 million to 10.5 million (≥93%), with a greater than two-fold increase among men aged 65 years and older (≥117%) and for low-HDI and medium-HDI countries/territories (≥160%). Cancer cases and deaths are projected to increase among working-age groups (≥39%) and very-high-HDI countries/territories (≥50%).
CONCLUSIONS: Substantial disparities in cancer cases and deaths were observed among men in 2022, and these are projected to widen by 2050. Strengthening health infrastructure, enhancing workforce quality and access, fostering national and international collaborations, and promoting universal health coverage are crucial to reducing cancer disparities and ensuring cancer equity among men globally.
摘要：
背景：男性表现出更高的可改变危险因素患病率，比如吸烟和饮酒，导致更高的癌症发病率和更低的生存率。关于男性全球癌症负担的综合证据，包括年龄组和国家的差异，是稀疏的。为了解决这个问题，作者分析了2022年男性的30种癌症类型，并预测了2050年。
方法：2022年GLOBOCAN估计值用于描述全球185个国家/地区男性的癌症统计数据。通过将年龄标准化死亡率除以发病率来计算死亡率与发病率之比（MIR）。
结果：2022年，在老年男性（65岁及以上；61％）中观察到罕见癌症类型（胰腺癌，91％）和人类发展指数较低的国家（HDI；74％）。从2022年到2050年，癌症病例预计将从1030万增加到1900万（≥84％）。预计死亡人数将从540万增加到1050万(≥93%),在65岁及以上的男性（≥117%）以及低HDI和中等HDI国家/地区（≥160%）中增加了两倍以上。在工作年龄组（≥39%）和HDI极高的国家/地区（≥50%），癌症病例和死亡人数预计将增加。
结论：2022年在男性中观察到癌症病例和死亡人数的巨大差异，预计到2050年这些差异将扩大。加强卫生基础设施建设，提高劳动力质量和准入，促进国家和国际合作，和促进全民健康覆盖对于减少癌症差异和确保全球男性癌症平等至关重要。
方法：2022年GLOBOCAN估计值用于描述全球185个国家/地区男性的癌症统计数据。通过将年龄标准化死亡率除以发病率来计算死亡率与发病率之比（MIR）。
结果：2022年，在老年男性（65岁及以上；61％）中观察到罕见癌症类型（胰腺癌，91％）和人类发展指数较低的国家（HDI；74％）。从2022年到2050年，癌症病例预计将从1030万增加到1900万（≥84％）。预计死亡人数将从540万增加到1050万(≥93%),在65岁及以上的男性（≥117%）以及低HDI和中等HDI国家/地区（≥160%）中增加了两倍以上。在工作年龄组（≥39%）和HDI极高的国家/地区（≥50%），癌症病例和死亡人数预计将增加。
结论：2022年在男性中观察到癌症病例和死亡人数的巨大差异，预计到2050年这些差异将扩大。加强卫生基础设施建设，提高劳动力质量和准入，促进国家和国际合作，和促进全民健康覆盖对于减少癌症差异和确保全球男性癌症平等至关重要。
